The patient impact of 10 years of ocrelizumab treatment in multiple sclerosis: Long-term data from the Phase III OPERA and ORATORIO studies

Authors
Category Primary study
ConferenceMSmilan2023
Year 2023
This article has no abstract
Epistemonikos ID: f1ed83f6f6d6ba9903da2aa680f1afea83b936e1
First added on: Jan 10, 2026